Division of Nephrology and Hypertension, Department of Internal Medicine, St Marianna University School of Medicine, Kanagawa, Japan.
Department of Nephrology, Inagi Municipal Hospital, Tokyo, Japan.
Perit Dial Int. 2023 Nov;43(6):457-466. doi: 10.1177/08968608231193240. Epub 2023 Aug 26.
This multi-institutional, observational study examined whether the outcomes after peritoneal dialysis (PD) catheter placement in Japan meet the audit criteria of the International Society for Peritoneal Dialysis (ISPD) guideline and identified factors affecting technique survival and perioperative complications.
Adult patients who underwent first PD catheter placement for end-stage kidney disease between April 2019 and March 2021 were followed until PD withdrawal, kidney transplantation, transfer to other facilities, death, 1 year after PD start or March 2022, whichever came first. Primary outcomes were time to catheter patency failure and technique failure, and perioperative infectious complications within 30 days of catheter placement. Secondary outcomes were perioperative complications. Appropriate statistical analyses were performed to identify factors associated with the outcomes of interest.
Of the total 409 patients, 8 who underwent the embedded catheter technique did not have externalised catheters. Of the 401 remaining patients, catheter patency failure occurred in 25 (6.2%). Technical failure at 12 months after PD catheter placement calculated from cumulative incidence function was 15.3%. On Cox proportional hazards model analysis, serum albumin (hazard ratio (HR) 0.44; 95% confidence interval (CI) 0.27-0.70) and straight type catheter (HR 2.14; 95% CI 1.24-3.69) were the independent risk factors for technique failure. On logistic regression analysis, diabetes mellitus was the only independent risk factor for perioperative infectious complications (odds ratio 2.70, 95% CI 1.30-5.58). The occurrence rate of perioperative complications generally met the audit criteria of the ISPD guidelines.
PD catheter placement in Japan was proven to be safe and appropriate.
这项多机构、观察性研究旨在检验日本腹膜透析(PD)导管置管术后的结局是否符合国际腹膜透析学会(ISPD)指南的审核标准,并确定影响技术生存率和围手术期并发症的因素。
2019 年 4 月至 2021 年 3 月期间,对接受首次 PD 导管置管治疗终末期肾病的成年患者进行随访,直至 PD 退出、肾移植、转至其他机构、死亡、PD 开始后 1 年或 2022 年 3 月(以先发生者为准)。主要结局为导管通畅失败和技术失败的时间,以及导管置管术后 30 天内的感染性并发症。次要结局为围手术期并发症。采用适当的统计分析方法确定与研究结果相关的因素。
在 409 例患者中,8 例采用嵌入式导管技术的患者未进行外置导管。在其余 401 例患者中,25 例(6.2%)发生导管通畅失败。采用累积发生率函数计算的 PD 导管置管后 12 个月时的技术失败率为 15.3%。在 Cox 比例风险模型分析中,血清白蛋白(风险比(HR)0.44;95%置信区间(CI)0.27-0.70)和直型导管(HR 2.14;95%CI 1.24-3.69)是技术失败的独立危险因素。在 logistic 回归分析中,糖尿病是围手术期感染性并发症的唯一独立危险因素(比值比 2.70,95%CI 1.30-5.58)。围手术期并发症的发生率总体上符合 ISPD 指南的审核标准。
日本的 PD 导管置管术被证明是安全且合适的。